// App-Quantinova.ai

OT1-07-05 : TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC)

Researchers

Presenter

  • Hope S Rugo

Principal Investigators

  • Aditya Bardia

  • Sara M. Tolaney

  • Carlos Arteaga

  • Javier Cortes

  • Joohyuk Sohn

  • Frederik Marm

  • Quan Hong

  • Scott Hofsess

  • Martin Olivo

  • Andr Fabrice

  • Peter Schmid

Medical Centers

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)

  • Universität Heidelberg and Universitätsklinikum Mannheim, Mannheim, Germany

  • Immunomedics Inc., Morris Plains, NJ

  • Institut Gustave-Roussy, Villejuif, France

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • United States

  • Spain

  • Republic of South Korea

  • Germany

  • France

  • United Kingdom

Companies

  • Immunomedics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • IMMU132

  • Capecitabine

  • Gemcitabine

  • Vinorelbine

  • Eribulin

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT03901339

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved